A 56-year-old woman with a history of lupus and laparoscopic Roux-en-Y gastric bypass (RYGB), complicated by a persistent anastomotic ulcer ultimately requiring partial gastrectomy and esophagojejunostomy, was referred for endoscopic management of an esophagojejunal anastomotic stricture.
Ten years after the RYGB, the patient was evaluated because of epigastric pain and intermittent black tarry stools. She was found to have a bleeding gastrojejunal anastomotic ulcer. She did not report the use of tobacco or significant use of anti-inflammatory agents, and her lupus was known to be well controlled since the time of initial bypass surgery. Because of nonhealing ulceration with associated iron deficiency, persistent epigastric abdominal pain, and 12-pound weight loss, the patient underwent an uncomplicated partial gastrectomy with esophagojejunostomy. Five months later, the patient was evaluated because of progressive dysphagia. An esophagram (Fig. 1A ) and upper endoscopy (Fig. 1B) revealed a benign-appearing esophagojejunal anastomotic stricture approximately 5 mm in initial diameter.
The patient underwent serial balloon dilations to 12 mm (performed every 2 weeks Â 3) (Fig. 1C) , without clinical or endoscopic response. Dilation beyond 12 mm was limited by deep mucosal/ submucosal tearing (Fig. 1D) .
The decision was made to pursue endoscopic placement of a lumen-apposing metal stent (LAMS) (Axios; Boston Scientific, Marlborough, Mass) for management of the refractory anastomotic stricture (Video 1, available online at www.VideoGIE.org). After uncomplicated placement of a 15 mm Â 10 mm LAMS (Fig. 1E) , the patient was discharged home, her diet was slowly advanced, and she experienced resolution of her dysphagia. One month after LAMS placement, repeated upper endoscopy was performed, and the stent was removed (Fig. 1F) . The anastomosis was widely patent and easily traversed. Five months after LAMS removal, the patient tolerated a nearly normal diet, and her weight had increased by 15 pounds.
In conclusion, LAMS placement may provide an effective management strategy for refractory, short, anastomotic strictures after the failure of serial dilations. Of note, this is an off-label use of LAMSs because they are not approved by the U.S. Food and Drug Administration for this indication.
